Abortion Pills Medicine in Riyadh

Abortion Pills Medicine in Riyadh

Confirmation of Pregnancy Termination

Patients should be scheduled for and return for a follow-up visitat approximately 14 days after administration of Mifepristone to confirm that the pregnancy is completely terminated and to assess the degree of bleeding. Vaginal bleeding is not an evidence of the termination of pregnancy, Termination can be confirmed by clinical examination or ultrasonographic scan. Lack of bleeding following treatment usually Indicates falluri; however, prolonged or heavy bleeding is not proof of a complete abortion. Medical abortion failures should be managed with surgical termination.

Ectopic Pregnancy

Mifepristone is contraindicated in patients with a confirmed or suspected actopic pregnancy since Mifepristone is not effective for terminating these pregnancies. There could be a possibility that a patient who is undergoing a medical abortion could have an undiagnosed ectopic pregnancy since some of the expected symptoms of a medical abortion may be similar to those of a ruptured ectopic pregnancy. The presence of an ectopic pregnancy may have been missed even if the patient underwent ultrasonography prior to being prescribed Mifepristone.

Misoprostol

Some authors suggest moistening Misoprostol with 3-4 drops of saline/distilled water when used for vaginal administration.

During the period immediately following the administration of Misoprostol, the patient may need medication for cramps or gastrointestinal symptoms. The patient should be given instructions on what to do if significant discomfort, excessive bleeding or other adverse reactions occur and should be given a phone number to call if she has questions following the administration of Misoprostol.

PRECAUTIONS

Pregnancy

Mifepristone and Misopristol is indicated for use in the termination of pregnancy (through 63 days pregnancy) and has no other approved indication for use during pregnancy. Patients who have an ongoing pregnancy at the last visit have a risk of foetal malformation resulting from the treatment. Surgical termination is recommended to manage medical abortion treatment failures.

Teratogenic Effects

Several reports in the literature indicate that prostaglandins, including Misoprostol, may have teratogenic effects in human beings. Skull defects, cranial nerve palsies, delayed growth and psychomotor development, facial malformation and limb defects have all been reported after exposure during the first trimester.

Lactation

Mifepristone

It is not known whether Mifepristone is excreted in human milk. Many hormones with a similar chemical structure, however, are excreted in breast milk. Since the effects of Mifepristone on infants are unknown, breast-feeding women should consult with their doctor to decide if they should discard their breast milk for a few days following administration of the medications.

Misoprostol

Although it is not known whether Misoprostol or Misoprostol acid is excreted in human milk, Misoprostol should not be administered to nursing mothers because the potential excretion of Misoprostol acid could cause diarrhoea in nursing infants.

Paediatric use

Safety and effectiveness of Mifepristone and Misoprostol in paediatric patients have not been established.